Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing

Gynecologic Oncology

Volumn 128, Issue 3, 2013, Pages 483-487

  Norquist, Barbara M ^a   Pennington, Kathryn P ^a   Agnew, Kathy J ^a   Harrell, Maria I ^a   Pennil, Christopher C ^a   Lee, Ming K ^a   Casadei, Silvia ^a   Thornton, Anne M ^a   Garcia, Rochelle L ^a   Walsh, Tom ^a   Swisher, Elizabeth M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

BRCA1; BRCA2; BROCA; Genetic testing; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84873742602     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.12.015     Document Type: Article

References (28)

1. T. Pal, J. Permuth-Wey, J.A. Betts, J.P. Krischer, J. Fiorica, and H. Arango BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases Cancer 104 12 2005 Dec 15 2807 2816
2. H.A. Risch, J.R. McLaughlin, D.E. Cole, B. Rosen, L. Bradley, and E. Kwan Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer Am J Hum Genet 68 3 2001 700 710
3. S. Zhang, R. Royer, S. Li, J.R. McLaughlin, B. Rosen, and H.A. Risch Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer Gynecol Oncol 121 2 2011 May 1 353 357
4. M.C. King, J.H. Marks, J.B. Mandell, and N.Y.B.C.S. Group Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science 302 5645 2003 Oct 24 643 646
5. S.R. Lakhani, S. Manek, F. Penault-Llorca, A. Flanagan, L. Arnout, and S. Merrett Pathology of ovarian cancers in BRCA1 and BRCA2 carriers Clin Cancer Res 10 7 2004 Apr 1 2473 2481
6. P.A. Shaw, J.R. McLaughlin, R.P. Zweemer, S.A. Narod, H. Risch, and R.H. Verheijen Histopathologic features of genetically determined ovarian cancer Int J Gynecol Pathol 21 4 2002 Oct 407 411
7. K.L. Bolton, G. Chenevix-Trench, C. Goh, S. Sadetzki, S.J. Ramus, and B.Y. Karlan Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer JAMA 307 4 2012 Jan 25 382 390
8. K. Alsop, S. Fereday, C. Meldrum, A. Defazio, C. Emmanuel, and J. George BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group J Clin Oncol 30 21 2012 Jul 20 2654 2663
9. S.M. Domchek, T.M. Friebel, S.L. Neuhausen, T. Wagner, G. Evans, and C. Isaacs Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study Lancet Oncol 7 3 2006 Mar 223 229
10. N.D. Kauff, S.M. Domchek, T.M. Friebel, M.E. Robson, J. Lee, and J.E. Garber Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study J Clin Oncol 26 8 2008 Mar 10 1331 1337
11. T.R. Rebbeck, N.D. Kauff, and S.M. Domchek Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers J Natl Cancer Inst 101 2 2009 Jan 21 80 87
12. H.E. Bryant, N. Schultz, H.D. Thomas, K.M. Parker, D. Flower, and E. Lopez Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 7035 2005 Apr 14 913 917
13. H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, and T.B. Richardson Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 7035 2005 Apr 14 917 921
14. J. Boyd, Y. Sonoda, M.G. Federici, F. Bogomolniy, E. Rhei, and D.L. Maresco Clinicopathologic features of BRCA-linked and sporadic ovarian cancer JAMA 283 17 2000 May 3 2260 2265
15. I. Cass, R.L. Baldwin, T. Varkey, R. Moslehi, S.A. Narod, and B.Y. Karlan Improved survival in women with BRCA-associated ovarian carcinoma Cancer 97 9 2003 May 1 2187 2195
16. A. Chetrit, G. Hirsh-Yechezkel, Y. Ben-David, F. Lubin, E. Friedman, and S. Sadetzki Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer J Clin Oncol 26 1 2008 Jan 1 20 25
17. D.M. Hyman, K.C. Long, E.J. Tanner, R.N. Grisham, A.G. Arnold, and J. Bhatia Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma Gynecol Oncol 126 2 2012 Aug 224 228
18. S.C. Rubin, I. Benjamin, K. Behbakht, H. Takahashi, M.A. Morgan, and V.A. LiVolsi Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1 N Engl J Med 335 19 1996 1413 1416
19. D.S. Tan, C. Rothermundt, K. Thomas, E. Bancroft, R. Eeles, and S. Shanley «BRCAness» syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations J Clin Oncol 26 34 2008 Dec 1 5530 5536
20. D. Yang, S. Khan, Y. Sun, K. Hess, I. Shmulevich, and A.K. Sood Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer JAMA 306 14 2011 Oct 12 1557 1565
21. T. Walsh, M.K. Lee, S. Casadei, A.M. Thornton, S.M. Stray, and C. Pennil Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing Proc Natl Acad Sci U S A 107 28 2010 Jul 13 12629 12633
22. T. Walsh, S. Casadei, M.K. Lee, C.C. Pennil, A.S. Nord, and A.M. Thornton Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing Proc Natl Acad Sci U S A 108 44 2011 Nov 1 18032 18037
23. Breast Cancer Information Core Databases Available from: http://www.nhgri.nih.gov/Intramural-research/Lab-transfer/Bic/
24. K.A. Metcalfe, I. Fan, J. McLaughlin, H.A. Risch, B. Rosen, and J. Murphy Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study Gynecol Oncol 112 1 2009 Jan 68 72
25. K.A. Schrader, J. Hurlburt, S.E. Kalloger, S. Hansford, S. Young, and D.G. Huntsman Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy Obstet Gynecol 120 2 Pt 1 2012 Aug 235 240
26. Genetic/Familial High-Risk Assessment: Breast and Ovarian Cancer 2012 [Available from: nccn.org.]
27. M.W. Audeh, J. Carmichael, R.T. Penson, M. Friedlander, B. Powell, and K.M. Bell-McGuinn Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 376 9737 2010 Jul 24 245 251
28. P.C. Fong, D.S. Boss, T.A. Yap, A. Tutt, P. Wu, and M. Mergui-Roelvink Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2 2009 Jul 9 123 134